文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

瑞德西韦、羟氯喹、洛匹那韦和干扰素β-1a治疗Covid-19住院患者的随机对照试验:WHO团结试验中期结果

Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
PubMed 文献 · N Engl J Med · 2020-12-02
一句话结论在住院Covid-19患者中,瑞德西韦、羟氯喹、洛匹那韦和干扰素β-1a方案对降低院内死亡率、减少机械通气启动或缩短住院时间均无明确获益。

WHO团结试验在30个国家405家医院随机纳入11330例Covid-19住院成人,比较瑞德西韦、羟氯喹、洛匹那韦(不含干扰素)、干扰素β-1a(含干扰素联合洛匹那韦)与各自对照(当地标准治疗但不使用该药)的院内死亡率。四项两两比较的死亡风险比分别为瑞德西韦0.95(95%CI 0.81–1.11,P=0.50)、羟氯喹1.19(95%CI 0.89–1.59,P=0.23)、洛匹那韦1.00(95%CI 0.79–1.25,P=0.97)、干扰素1.16(95%CI 0.96–1.39,P=0.11)。任何药物均未明确降低死亡率(总体或亚组)、未减少机械通气启动、未缩短住院时间。

要点

  • 住院Covid-19患者中,瑞德西韦与对照相比院内死亡风险比为0.95(95%CI 0.81–1.11,P=0.50),无明确获益。
  • 羟氯喹死亡风险比1.19(95%CI 0.89–1.59,P=0.23),洛匹那韦1.00(95%CI 0.79–1.25,P=0.97),干扰素1.16(95%CI 0.96–1.39,P=0.11),均无明确获益。
  • 任何药物均未明确降低死亡率(总体或亚组)、未减少机械通气启动、未缩短住院时间。
  • 随机化时已接受机械通气者28天死亡率39.0%,未接受者9.5%;总28天死亡率11.8%。
  • 中期依从性94–96%,交叉率2–6%;共1253例死亡,死亡中位日第8天(IQR 4–14)。

适用人群与场景

  • 纳入:Covid-19住院成人,在405家医院(30个国家)随机分组。
  • 随机化时已接受机械通气者28天死亡率39.0%,未接受者9.5%。
  • 排除人群:原文未提及。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及具体药物剂量、给药途径、频次或目标值。
  • 试验药物方案:瑞德西韦、羟氯喹、洛匹那韦(不含干扰素)、干扰素β-1a(含干扰素联合洛匹那韦),与各自对照(当地标准治疗但不使用该药)比较。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:WHO团结试验中期结果,随机对照试验;30个国家405家医院;11330例Covid-19住院成人随机分组。
  • 分组:瑞德西韦2750例,羟氯喹954例,洛匹那韦(不含干扰素)1411例,干扰素2063例(其中651例干扰素联合洛匹那韦),无试验药物4088例。
  • 主要终点院内死亡率:瑞德西韦301/2743 vs 对照303/2708,RR 0.95(95%CI 0.81–1.11,P=0.50);羟氯喹104/947 vs 84/906,RR 1.19(95%CI 0.89–1.59,P=0.23);洛匹那韦148/1399 vs 146/1372,RR 1.00(95%CI 0.79–1.25,P=0.97);干扰素243/2050 vs 216/2050,RR 1.16(95%CI 0.9
  • 共1253例死亡,死亡中位日第8天(IQR 4–14);28天Kaplan-Meier死亡率11.8%(随机化时已接受机械通气者39.0%,否则9.5%)。
  • 任何药物均未明确降低死亡率(总体或亚组)、未减少机械通气启动、未缩短住院时间。
  • 中期依从性94–96%,交叉率2–6%。

证据类型、等级与局限

  • 证据类型:随机对照试验(WHO团结试验中期结果)。
  • 证据等级或推荐强度:原文未提及。
  • 局限:中期分析;原文未提及其他局限。

对床旁实践的改变

  • 对于Covid-19住院患者,不应期望瑞德西韦、羟氯喹、洛匹那韦或干扰素β-1a方案能降低院内死亡率、减少机械通气启动或缩短住院时间。
  • 随机化时已接受机械通气者28天死亡率39.0%,未接受者9.5%,提示病情严重程度与预后相关。

指南或共识出处

  • 原文未提及指南或共识名称;试验注册号:ISRCTN83971151;ClinicalTrials.gov NCT04315948。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs - remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a - in patients hospitalized with coronavirus disease 2019 (Covid-19).

METHODS: We randomly assigned inpatients with Covid-19 equally between one of the trial drug regimens that was locally available and open control (up to five options, four active and the local standard of care). The intention-to-treat primary analyses examined in-hospital mortality in the four pairwise comparisons of each trial drug and its control (drug available but patient assigned to the same care without that drug). Rate ratios for death were calculated with stratification according to age and status regarding mechanical ventilation at trial entry.

RESULTS: At 405 hospitals in 30 countries, 11,330 adults underwent randomization; 2750 were assigned to receive remdesivir, 954 to hydroxychloroquine, 1411 to lopinavir (without interferon), 2063 to interferon (including 651 to interferon plus lopinavir), and 4088 to no trial drug. Adherence was 94 to 96% midway through treatment, with 2 to 6% crossover. In total, 1253 deaths were reported (median day of death, day 8; interquartile range, 4 to 14). The Kaplan-Meier 28-day mortality was 11.8% (39.0% if the patient was already receiving ventilation at randomization and 9.5% otherwise). Death occurred in 301 of 2743 patients receiving remdesivir and in 303 of 2708 receiving its control (rate ratio, 0.95; 95% confidence interval [CI], 0.81 to 1.11; P = 0.50), in 104 of 947 patients receiving hydroxychloroquine and in 84 of 906 receiving its control (rate ratio, 1.19; 95% CI, 0.89 to 1.59; P = 0.23), in 148 of 1399 patients receiving lopinavir and in 146 of 1372 receiving its control (rate ratio, 1.00; 95% CI, 0.79 to 1.25; P = 0.97), and in 243 of 2050 patients receiving interferon and in 216 of 2050 receiving its control (rate ratio, 1.16; 95% CI, 0.96 to 1.39; P = 0.11). No drug definitely reduced mortality, overall or in any subgroup, or reduced initiation of ventilation or hospitalization duration.

CONCLUSIONS: These remdesivir, hydroxychloroquine, lopinavir, and interferon regimens had little or no effect on hospitalized patients with Covid-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay. (Funded by the World Health Organization; ISRCTN Registry number, ISRCTN83971151; ClinicalTrials.gov number, NCT04315948.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2020. PMID: 33264556. doi:10.1056/NEJMoa2023184

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。